16 July – 20 July 2021
₹1073 to ₹1083
As an investor you must be interested that which IPO to subscribe. Every intelligent investor like you strongly believes in doing some basic and possible advance research for the company you are going to invest.
Research of one entity takes lots of time and energy to understand and conclude. This is one of the biggest pain points for the investor who are working profession and self-employed, due to their time constrain.
There a lot of websites, blogs available in public domain, which claim to be the best research portals. Some of these are free of cost and some of these are paid as well. There are lots of such free blogs just promote the product to generate traffic or buzz in the market and get paid for their promotion from company or marketing agency.
In this article I will be coveting details for Tatva Chintan IPO, before subscribing any IPO it is important to have complete understanding of the IPO. To explain it in more details, I have structured the details of the IPO as mentioned listed below
What does Tatva Chintan Do
Tatva Chintan Pharma Chem Limited is specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”).
Tatva Chintan Pharma Chem Limited is the largest commercial manufacturer of SDAs for zeolites in India and second largest globally. Tatva Chintan Pharma is one of the leading global producers of an entire range of PTCs in India.
The company supplies its product to automotive, petroleum, pharmaceutical, agro chemicals, paints, coatings, dyes, pigments, personal care, flavour and fragrances industries.
The company exports its product to 25 countries i.e., China, USA, Japan, Germany, UK.
History of the company
Tatva Chintan Pharma Chem Limited is Gujarat based company.
It was incorporated in 1996.
It has two subsidiaries company; one is based in the USA and another is based in Europe.
Tatva Chintan Pharma achieved its first Rs. 500 million revenue in 2013 and posted its first Rs. 1 billion turnovers in 2015.
The company recorded its first Rs. 2 billion turnover milestone in 2020.
Promoter of the company
Tatva Chintan Pharma Chem Limited (Formerly known as Tatva Chintan Pharma Chem Private Limited) was promoted by Chintan Shah, Ajay Patel and Shekhar Somani, who each have over 24 years in the specialty chemicals manufacturing industry.
Chintan Nitinkumar Shah: Mr Shah is the Managing Director on our Board. He holds B.E degree in computer science from M. S. University, Baroda. Mr. Shah takes care of business development, finance and information services. He brings over 24 years of experience in same field.
Ajaykumar Mansukhlal Patel: Mr. Patel is a Whole Time Director on our Board. He holds B.E degree in chemical engineering from Maharaja Sayajirao University, Baroda. Mr. Patel was previously associated with Sun Pharmaceutical Industries Limited as Officer – Chemical Engineering.
Shekhar Rasiklal Somani: Mr Somani is also Whole Time Director on our Board. Mr Somani holds a bachelor’s degree in pharmacy from the Maharaja Sayajirao University, Baroda. He manages business development, production controlling, quality, and supply chain management.
What is the end use of the funds?
The company will utilise the fresh issue of Rs 225 crore worth of shares to fund its capex plans like Dahej manufacturing plant and upgrade its Vadodara R&D facility.
What is tentative schedule/time table of the IPO
IPO Open Date
Jul 16, 2021
IPO Close Date
Jul 20, 2021
Basis of Allotment Date
Jul 26, 2021
Initiation of Refunds
Jul 27, 2021
Credit of Shares to Demat Account
Jul 28, 2021
IPO Listing Date
Jul 29, 2021
What is offering price and GMP of IPO
The company has fixed price band of the issue at Rs 1,073-1,083 per share.
An investor can bid for a minimum of 13 shares and in multiples thereafter.
There is good demand of tatva Chinta Phtarma shares in the grey market.
The grey market premium stood at Rs. 690 per share as on July 16, 2021, which is approximate 64% above the IPO offer price.
GMP for the share was at Rs. 525 on July 14, 2021.
We recommend to subscribe this IPO, as the company is a niche global player in the specialty chemicals segment with SDAs at the centre stage, having a globally-renowned clientele and reasonable valuations compared with its listed peers.
Your views are always welcome, do review and leave your valuable inputs in the form of comments about the IPO, this helps community members to understand it more.
Disclaimer: We are promoting financial literacy in India. The content published is purely for educational and general information purpose. We are not a SEBI registered financial advisor. Hence, we are not providing financial and investment advisory services. You are and will be solely responsible for your own money and decisions you take. Please consult a SEBI registered advisor for any kind of investment / financial advice.